Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

Autor: Michaut M; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., Chin SF; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK., Majewski I; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., Severson TM; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., Bismeijer T; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., de Koning L; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France., Peeters JK; Agendia NV, Science Park 406, 1098 XH Amsterdam, The Netherlands., Schouten PC; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., Rueda OM; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK., Bosma AJ; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., Tarrant F; Cancer Biology and Therapeutics Laboratory, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.; OncoMark Limited, NovaUCD, Belfield Innovation Park, Dublin 4, Ireland., Fan Y; Cancer Biology and Therapeutics Laboratory, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland., He B; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France., Xue Z; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., Mittempergher L; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., Kluin RJ; Genomic Core Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., Heijmans J; Agendia NV, Science Park 406, 1098 XH Amsterdam, The Netherlands., Snel M; Agendia NV, Science Park 406, 1098 XH Amsterdam, The Netherlands., Pereira B; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK., Schlicker A; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., Provenzano E; Cambridge Experimental Cancer Medicine Centre (ECMR) and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.; Cambridge Breast Unit and Cambridge University Hospitals, NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK., Ali HR; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.; Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QP, UK., Gaber A; Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, SE-221 85 Lund, Sweden., O'Hurley G; OncoMark Limited, NovaUCD, Belfield Innovation Park, Dublin 4, Ireland., Lehn S; Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, SE-221 85 Lund, Sweden., Muris JJ; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., Wesseling J; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., Kay E; Department of Pathology, RCSI ERC, Beaumont Hospital, Dublin 9, Ireland., Sammut SJ; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK., Bardwell HA; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK., Barbet AS; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France., Bard F; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France., Lecerf C; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France., O'Connor DP; Cancer Biology and Therapeutics Laboratory, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland., Vis DJ; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., Benes CH; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., McDermott U; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK., Garnett MJ; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK., Simon IM; Agendia NV, Science Park 406, 1098 XH Amsterdam, The Netherlands., Jirström K; Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, SE-221 85 Lund, Sweden., Dubois T; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France., Linn SC; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Division of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Gallagher WM; Cancer Biology and Therapeutics Laboratory, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.; OncoMark Limited, NovaUCD, Belfield Innovation Park, Dublin 4, Ireland., Wessels LF; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Department of EEMCS, Delft University of Technology, Delft, The Netherlands., Caldas C; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.; Cambridge Experimental Cancer Medicine Centre (ECMR) and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.; Cambridge Breast Unit and Cambridge University Hospitals, NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK.; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0QQ, UK., Bernards R; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Agendia NV, Science Park 406, 1098 XH Amsterdam, The Netherlands.; Cancer Genomics Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Publikováno v: Scientific reports [Sci Rep] 2016 Jan 05; Vol. 6, pp. 18517. Date of Electronic Publication: 2016 Jan 05.

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.

Autor: Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ, Berns EM, Vermorken JB, van Diest PJ, Linn SC

Publikováno v: Breast cancer research : BCR [Breast Cancer Res] 2014 Jan 27; Vol. 16 (1), pp. R13. Date of Electronic Publication: 2014 Jan 27.

Urinary granzyme A mRNA is a biomarker to diagnose subclinical and acute cellular rejection in kidney transplant recipients.

Autor: van Ham SM; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, Amsterdam, The Netherlands. m.vanham@sanquin.nl, Heutinck KM, Jorritsma T, Bemelman FJ, Strik MC, Vos W, Muris JJ, Florquin S, Ten Berge IJ, Rowshani AT

Publikováno v: Kidney international [Kidney Int] 2010 Nov; Vol. 78 (10), pp. 1033-40. Date of Electronic Publication: 2010 Aug 18.

T-cell response in B-cell lymphomas: favorable or unfavorable?

Autor: Oudejans JJ, Muris JJ, Cillessen SA, Meijer CJ

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2008 Apr 15; Vol. 14 (8), pp. 2514; author reply 2515-6.

Expression of c-FLIP is primarily detected in diffuse large B-cell lymphoma and Hodgkin's lymphoma and correlates with lack of caspase 8 activation.

Autor: van Houdt IS; Department of Pathology, VUMC, Amsterdam, The Netherlands., Muris JJ, Hesselink AT, Kramer D, Cillessen SA, Moesbergen LM, Vos W, Hooijberg E, Meijer CJ, Kummer JA, Oudejans JJ

Publikováno v: Histopathology [Histopathology] 2007 Dec; Vol. 51 (6), pp. 778-84.